Impact of Perampanel for First-Episode Seizures versus Usual Care on Clinical Outcome and Safety Profile Aspects of the Thai Experience
Panu Boontoterm, Siraruj Sakoolnamarka, Karanarak Urasyanandana, Pusit Fuengfoo · 2024
Read Impact of Perampanel for First-Episode Seizures versus Usual Care on Clinical Outcome and Safety Profile Aspects of the Thai Experience by Panu Boontoterm, Siraruj Sakoolnamarka, Karanarak Urasyanandana, Pusit Fuengfoo (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11664051.txt.
Description
Panu Boontoterm and co-authors report Thai experience with perampanel as the first drug tried after a first seizure, in patients whose epilepsy stems from brain injury or tumors. For them, fast seizure control protects a brain already under threat. Perampanel, a third-generation agent with a distinct mechanism, is usually reserved for later lines.
Eighty-four patients were followed prospectively: thirty-six started on perampanel alone, forty-eight on usual first-line drugs. Seizure reduction at twenty-eight days, freedom from seizures at six months, adherence, and side effects were compared. Moving a later-line drug to the front is a bet on tolerability and speed; this study prices that bet in a real hospital population.
Catalog record
| CREATOR | Panu Boontoterm, Siraruj Sakoolnamarka, Karanarak Urasyanandana, Pusit Fuengfoo |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 21 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |